BMS, Merck end Pargluva pact

Share this article:
Bristol-Myers Squibb said it will terminate its collaborative agreement with Merck for Pargluva (muraglitazar), the investigational drug to treat type 2 diabetes.
BMS had announced in October that it was weighing whether to end the collaboration, following an FDA request for additional information about Pargluva's cardiovascular safety. To comply with the request, BMS said it would need to run additional studies that could take as long as five years.
The FDA had said it would not approve Pargluva without the additional data on cardiovascular risk, despite the fact that an advisory panel voted overwhelmingly to approve the drug.
Researchers from the Cleveland Clinic also have recommended a large study examining Pargluva's long-term heart effect.
Under their termination agreement, BMS and Merck agreed that all rights to muraglitazar returned to BMS as of Dec. 21. BMS also retained a back-up compound to muraglitazar.
The delay has caused BMS to consider a range of options, it said, including terminating further development of the diabetes compound. The firm said it is continuing discussions with the FDA.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.